3D bioprinting is experiencing rapid growth as the technology continues to evolve. This is certainly the case in Australia and AXT, who are already well entrenched in the field are pleased to announce that they are strengthening their position by partnering with CELLINK.
BMS and Prime ink potential $3.5bn deal to develop T cell therapies – Pharmaceutical Technology
Ex vivo gene therapy offers a potential one-time, curative solution for a host of genetic diseases. Image: Getty Images/ Perception7 Bristol Myers Squibb (BMS) has